{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-066248","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.957559+00:00","generated_at":"2026-06-07T21:10:42.760924+00:00","sec_items":["2.05","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Candel Therapeutics announces 50% workforce reduction, restructuring to focus on CAN-3110 and enLIGHTEN platform","bullets":["Approximately 50% workforce reduction; one-time restructuring charge of ~$0.7M in Q4 2023.","Cash runway extended into Q4 2024; company prioritizes CAN-3110 development and enLIGHTEN platform.","Key CAN-2409 readouts in 2024: NSCLC overall survival (Q2), pancreatic interim (Q2), prostate (Q4).","Company will explore partnering opportunities for CAN-2409 to reduce commercial manufacturing costs.","Initial CAN-3110 repeated injection data in recurrent high-grade glioma expected H2 2024; new enLIGHTEN data Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-066248","json":"https://secwatch.observer/filing/0000950170-23-066248.json","markdown":"https://secwatch.observer/filing/0000950170-23-066248.md","text":"https://secwatch.observer/filing/0000950170-23-066248.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023066248/0000950170-23-066248-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023066248/cadl-20231126.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:10:42.760924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4d61f0b0e17f475bba457f2e1ed302725cd9e689","claim":"Candel Therapeutics, Inc. announced a restructuring with charges of approximately $0.7 million affecting the Company (approximately 50%).","evidence_excerpt":"On November 26, 2023, the Board of Directors (the “Board”) of Candel Therapeutics, Inc (the \"Company\") approved a strategic restructuring to focus on continuation and expansion of development of CAN-3110 as well as the enLIGHTEN TM Discovery Platform, and reducing the Company’s workforce by approximately 50%, as well as reducing expenses associated with enabling commercial readiness of CAN-2409, while maintaining and prioritizing key clinical readouts in 2024 (the “Restructuring Plan”). In connection with the Restructuring Plan, the Company estimates that it will incur a one-time restructuring charge of approximately $0.7 million in the fourth quarter of 2023 related to severance and healthcare and related benefits costs.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841387/000095017023066248/0000950170-23-066248-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.7 million"},{"label":"Affected area","value":"the Company"},{"label":"Headcount","value":"approximately 50%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}